AMTI - Applied Molecular Transport oral ulcerative colitis candidate fails in mid-stage trial

• AMT-101, an oral candidate for ulcerative colitis from Applied Molecular Transport ( NASDAQ: AMTI ), has failed in a phase 2 trial .
• Top-line data showed that that the clinical remission rate was higher in the placebo group than the treatment group.
• AMT-101 was given as a monotherapy.
• The company said it would pursue the candidate for chronic pouchitis, for which it has Orphan Drug status. A partner will be needed before it can move into phase 3 for this indication.
• Seeking Alpha's Quant Rating views Applied Molecular Transport ( AMTI ) as a strong sell.

For further details see: